Agappe Diagnostics Of India Expects 300 Percent Growth This Year
This article was originally published in PharmAsia News
Executive Summary
India's Agappe Diagnostics says it expects a 300 percent growth over the rest of this year, three times the percentage growth of the previous year. Agappe attributed the expected gains to an appreciating euro and high prices in Western countries. Agappe's managing director, Thomas John, said his firm expects to acquire technology to help it take advantage of India's lower manufacturing costs. John said the past year's situation of an appreciating euro and high Western production costs caused problems in reducing prices, but the technology aspect was expected to be an offset. (Click here for more